A University of Cincinnati study has shed light on differences in pancreatic tumors, offering insights that may lead to more personalized cancer treatments. The research analyzed 22 pancreatic tumors from patients across the U.S. of different racial backgrounds, focusing on variations in cancer cells and the immune response.
Study Details and Findings
The study included seven Black patients and 15 non-African American patients, with results published in the journal Cancer Research. It found that tumors from Black patients contained fewer of the most common type of pancreatic cancer cells but had more cells with diverse characteristics. Some of these characteristics have links to drug resistance, though it’s unclear if they affect treatment outcomes.
Additionally, tumors from Black patients had more B cells — a type of immune cell — and larger clusters of these cells. Some B cells may suppress the body’s cancer response, but the significance remains uncertain. The study noted no significant genetic differences driving the disease between the groups. This research emphasizes including diverse ancestries in cancer studies to avoid oversight in finding a cure.
Challenges in Treatment
Dr. Raymond Wadlow, a gastrointestinal oncologist, highlighted the difficulty of using immunotherapy for pancreatic cancer. The disease often subverts the immune system, complicating treatment.
Pancreatic cancer is 20% more prevalent in Black Americans compared to non-African Americans. Differences in cell behavior, immune interaction, and surrounding tissue may contribute to treatment challenges. Such disparities highlight the need for individualized medical approaches.
Further Research and Implications
Lead author Nina Steele, Ph.D., emphasized the importance of studying diverse patient backgrounds. Such research could enhance understanding of cancer disparities and guide tailored treatments. However, more extensive studies are necessary to link these findings with treatment outcomes decisively.
Wadlow advised newly diagnosed patients to consider hereditary genetic testing to identify mutations that affect both patients and relatives. More inclusive clinical trials are crucial for developing effective treatments for all patients.
